Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PET-adapted therapy versus standard BEACOPPesc in advanced or high-risk Hodgkin lymphoma
2010-022844-19Phase 3Completed
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Dec 2010
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine and 4 more in classical Hodgkin lymphoma (cHL) (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Progression-free survival. Started Dec 2010; status: completed.
02
Drugs
bleomycinetoposidedoxorubicincyclophosphamidevincristine
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on 2010-022844-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022844-19.